PURPOSE: To quantify the effect of sublingual isosorbide dinitrate (ISDN) administration on coronary magnetic resonance (MR) imaging. MATERIALS AND METHODS: Written informed consent was obtained from all participants, and the HIPAA-compliant protocol was approved by the Institutional Review Board. Coronary MR imaging was performed at 1.5 T before and after administration of ISDN (2.5 or 5 mg) in 25 healthy adult volunteers (mean age, 23 years +/- 4; nine men, 16 women) with three-dimensional targeted (n = 20, randomized into four groups) orwhole-heart (n = 5) acquisitions with gradient-recalled echo (GRE) or balanced steady-state free precession (SSFP) sequences. Image quality was assessed by two cardiologists on a four-point scale. Signal-to-noise ratio (SNR), vessel diameter, and vessel sharpness were characterized. A linear mixed-effects model was used for data analysis. A P value of less than .05 was considered to indicate a significant difference. RESULTS: The maximum SNR enhancement with 5 mg of ISDN (GRE: 22.0% +/- 10.7%; SSFP: 20.1% +/- 6.0%) was similar (P > .05) to that with 2.5 mg (GRE: 21.9% +/- 5.4%; SSFP: 19.1% +/- 3.0%). However, the time to maximum SNR enhancement for the 5-mg dose (15.5 minutes +/- 6.0) was earlier (P < .01) than that for 2.5 mg (23.5 minutes +/- 6.7). The increase in vessel diameter with 5 mg of ISDN was greater than that with 2.5 mg (P < .05 for both GRE and SSFP sequences). The coronary images were sharper after ISDN administration (P < .03). Subjective image quality score significantly improved after ISDN administration for GRE images (P < .05 for both doses) but was similar for SSFP images (P = .24 for 2.5 mg; P = .27 for 5 mg). Whole-heart coronary SNR was improved about 10% after ISDN administration (P < .05). CONCLUSION:Sublingual ISDN improves coronary MR imaging SNR. Practitioners need to consider the dose and temporal effects of ISDN when performing coronary MR imaging. (c) RSNA, 2010.
RCT Entities:
PURPOSE: To quantify the effect of sublingual isosorbide dinitrate (ISDN) administration on coronary magnetic resonance (MR) imaging. MATERIALS AND METHODS: Written informed consent was obtained from all participants, and the HIPAA-compliant protocol was approved by the Institutional Review Board. Coronary MR imaging was performed at 1.5 T before and after administration of ISDN (2.5 or 5 mg) in 25 healthy adult volunteers (mean age, 23 years +/- 4; nine men, 16 women) with three-dimensional targeted (n = 20, randomized into four groups) or whole-heart (n = 5) acquisitions with gradient-recalled echo (GRE) or balanced steady-state free precession (SSFP) sequences. Image quality was assessed by two cardiologists on a four-point scale. Signal-to-noise ratio (SNR), vessel diameter, and vessel sharpness were characterized. A linear mixed-effects model was used for data analysis. A P value of less than .05 was considered to indicate a significant difference. RESULTS: The maximum SNR enhancement with 5 mg of ISDN (GRE: 22.0% +/- 10.7%; SSFP: 20.1% +/- 6.0%) was similar (P > .05) to that with 2.5 mg (GRE: 21.9% +/- 5.4%; SSFP: 19.1% +/- 3.0%). However, the time to maximum SNR enhancement for the 5-mg dose (15.5 minutes +/- 6.0) was earlier (P < .01) than that for 2.5 mg (23.5 minutes +/- 6.7). The increase in vessel diameter with 5 mg of ISDN was greater than that with 2.5 mg (P < .05 for both GRE and SSFP sequences). The coronary images were sharper after ISDN administration (P < .03). Subjective image quality score significantly improved after ISDN administration for GRE images (P < .05 for both doses) but was similar for SSFP images (P = .24 for 2.5 mg; P = .27 for 5 mg). Whole-heart coronary SNR was improved about 10% after ISDN administration (P < .05). CONCLUSION: Sublingual ISDN improves coronary MR imaging SNR. Practitioners need to consider the dose and temporal effects of ISDN when performing coronary MR imaging. (c) RSNA, 2010.
Authors: M Stuber; R M Botnar; P G Danias; D K Sodickson; K V Kissinger; M Van Cauteren; J De Becker; W J Manning Journal: J Am Coll Cardiol Date: 1999-08 Impact factor: 24.094
Authors: Murat Ozgun; Andreas Hoffmeier; Marc Kouwenhoven; René M Botnar; Matthias Stuber; Hans Heinrich Scheld; Warren J Manning; Walter Heindel; David Maintz Journal: AJR Am J Roentgenol Date: 2005-07 Impact factor: 3.959
Authors: Masahiro Terashima; Craig H Meyer; Brian G Keeffe; Eric J Putz; Erasmo de la Pena-Almaguer; Phillip C Yang; Bob S Hu; Dwight G Nishimura; Michael V McConnell Journal: J Am Coll Cardiol Date: 2005-01-04 Impact factor: 24.094
Authors: Mehmet Akçakaya; Tamer A Basha; Raymond H Chan; Hussein Rayatzadeh; Kraig V Kissinger; Beth Goddu; Lois A Goepfert; Warren J Manning; Reza Nezafat Journal: Magn Reson Med Date: 2012-03-05 Impact factor: 4.668
Authors: Peng Hu; Jonathan Chan; Long H Ngo; Jouke Smink; Beth Goddu; Kraig V Kissinger; Lois Goepfert; Thomas H Hauser; Neil M Rofsky; Warren J Manning; Reza Nezafat Journal: Magn Reson Med Date: 2010-11-30 Impact factor: 4.668